List of Goprelto drug patents

Goprelto is owned by Genus Lifesciences.

Goprelto contains Cocaine Hydrochloride.

Goprelto has a total of 12 drug patents out of which 0 drug patents have expired.

Goprelto was authorised for market use on 14 December, 2017.

Goprelto is available in solution;nasal dosage forms.

Goprelto can be used as method of administering a local anesthetic to the mucous membranes in patients with renal impairment, method of administering a local anesthetic to the mucous membranes, method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes, method of administering a local anesthetic to the mucous membranes; method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes, method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; method of administering a local anesthetic to the mucous membranes in patients with renal impairment; method of administering a local anesthetic to the mucous membranes in geriatric patients, method for the induction of local anesthesia of the mucous membranes, method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment, method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment.

Drug patent challenges can be filed against Goprelto from December, 2021.

The generics of Goprelto are possible to be released after 07 February, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016407 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US9867815 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10413505 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10420760 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10149843 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10933060 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10973811 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10987347 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10894012 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10857095 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US10231961 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

US11040032 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same
Feb, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 14 December, 2017

Treatment: Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic to the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Method for the induction of local anesthesia of the mucous membranes

Dosage: SOLUTION;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in